Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, multicenter, Phase 2 study of lenvatinib in combination with everolimus in participants with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease. The primary objective of the study is to evaluate the objective response rate (ORR). This study consists of three phases: a Pretreatment Phase (Screening and Baseline Periods), a Treatment Phase (starting Cycle 1, Day 1), and a Posttreatment Phase (End of Treatment Visit and survival Follow-up).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02915783
Study type Interventional
Source Eisai Inc.
Contact
Status Completed
Phase Phase 2
Start date February 20, 2017
Completion date November 2, 2021